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Background: Recent evidence suggests that functional intratumorous lymph vessels may be absent from
some human cancers. This could result from either the failure of tumours to induce lymphangiogenesis, or
the collapse of lymph vessels, caused by high interstitial tumour pressure.
Methods: To differentiate between these two hypotheses, paraffin wax embedded clinical specimens from
normal breast (n = 13), usual ductal hyperplasia (n = 11), ductal carcinoma in situ (n = 21), and
invasive breast cancer (n = 40) were compared for lymphatic and blood vessel density by
immunohistochemistry with antibodies to the lymphatic endothelial hyaluronan receptor (LYVE-1) and
CD31, respectively.
Results: Lymph vessel density was lower than blood vessel density in normal breast tissue. Within breast
lobuli, lymph vessels were absent. In premalignant lesions blood microvessel density increased, whereas
no increase in lymph vessels could be seen intralesionally. In invasive cancers, lymph vessels were absent
in all but a few cases, where probably some pre-existing lymph vessels remained, although blood
microvessel density was once again increased.
Conclusion: Unlike angiogenesis, lymphangiogenesis is absent during breast carcinogenesis. This, and not
rising interstitial pressure caused by an increase in the size of lesions, explains the absence of
intratumorous lymph vessels in invasive breast cancer.
M
etastasis of breast cancer occurs by the invasion of
local tissue, by haematogenous spread, or by lym-
phatic spread. Much is known about the formation of
new blood vessels as a mechanism to support haematogenous
spread and facilitate tumour growth. In contrast, little is
known about the mechanisms involved in lymphatic spread.
For a long time, this was because of a lack of knowledge
about lymphangiogenic factors and the lack of suitable
markers to distinguish between blood endothelial and
lymphatic endothelial cells.
Recently, however, two members of the vascular endothe-
lial growth factor (VEGF) family, VEGF-C1 and VEGF-D,2
were found to be of importance in the induction of lym-
phangiogenesis. Vascular endothelial growth factor receptor-
3 (VEGFR-3/Flt4) is the lymph vessel specific receptor
tyrosine kinase specific for VEGF-C and VEGF-D.3 Unfor-
tunately, VEGFR-3 was also found to be expressed on
intratumorous blood vessels, making it less useful for the
detection of lymphatics in tumours.4 5
A more specific marker for lymph vessels is LYVE-1, a
receptor for hyaluronan, which is expressed early during the
development of lymphatic endothelium.6 7 Furthermore,
podoplanin,8 a glycoprotein of podocytes, and Prox I, a
homeobox transcription factor,9 10 are used for the detection
of lymphatics. Identification of these lymph vessel specific
markers has facilitated the study of lymphangiogenic growth
factors and intratumorous lymphangiogenesis.
It was found that VEGF-C expression is upregulated in
many solid tumours, and its expression correlated with
lymph node metastasis and lung metastases in breast cancer.1
Furthermore, in transgenic and xenotransplanted mice,
overexpression of the VEGF-C or VEGF-D ligands induced
intratumorous lymphangiogenesis.11–13 Investigation of lymph
vessel patterns in spontaneously arising tumours, such as
head and neck squamous cell carcinoma (HNSCC), showed
that proliferating lymphatics occur in human cancers, and
may in some cases contribute to lymph node metastasis.14
Investigation of intratumorous lymphatics in HNSCC showed
that a high intratumorous lymph vessel density (LVD) is
associated with a higher risk of local relapse, in addition to a
poor prognosis, and that peritumorous LVD is associated with
a better prognosis.14 15 The presence of intratumorous lym-
phatics was also shown in melanoma.16 17 Other studies
showed that peritumorous lymphatic vessel counts correlated
with a poor prognosis in patients with breast cancer18 and
cervical cancer.19 20
‘‘Our study was undertaken to investigate lymphangio-
genesis during breast carcinogenesis and to evaluate two
possible explanations for the putative absence of intratu-
morous lymphatics’’
In contrast to the above findings, the absence of intra-
tumorous lymph vessels was first described in a murine
sarcoma model.21 In this model, lymph vessels were absent,
although all lymphatic factors necessary to induce lymphan-
giogenesis were present. The authors suggested that this was
caused by high intratumorous pressure, which resulted in
collapse of the proliferating lymph vessels. Recently Padera et
al examined intratumorous lymph vessels in mouse tumours
overexpressing VEGF-C.22 Using functional and biochemical
investigations, no functional intratumorous vessels could
be found in these experimental tumours. Furthermore, the
investigation of lymph vessels in human lung tumour
specimens showed the absence of LYVE-1 positive vessels.
Most of these tumours showed marginally raised intratu-
morous pressure, indicating that pressure might play a role in
the absence of intratumorous lymphatics in vivo.
Abbreviations: BVD, blood vessel density/mm2; DCIS, ductal
carcinoma in situ; HNSCC, head and neck squamous cell carcinoma;
LVD, lymph vessel density/mm2; NHS, normal human serum; TBS, Tris
buffered saline; VEGF, vascular endothelial growth factor; VEGFR,
vascular endothelial growth factor receptor
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Our study was undertaken to investigate lymphangiogen-
esis during breast carcinogenesis and to evaluate two possible
explanations for the putative absence of intratumorous
lymphatics: increased interstitial pressure causing collapse
of lymph vessels or failure to induce lymphangiogenesis as a
result of other factors. To differentiate between these two
hypotheses during breast cancer carcinogenesis, we com-
pared lymph vessel with blood vessel patterns in normal
breast tissue and different proliferative breast lesions,
including neoplastic ones (ductal hyperplasia, ductal carci-
noma in situ (DCIS), and invasive breast cancer).
MATERIALS AND METHODS
Patients
Tissue sections containing breast tissue were obtained from
tissue blocks of randomly selected patients, which had been
deposited in the tissue banks of the pathology departments of
the VU University Medical Centre, Amsterdam and the Gooi-
Noord Hospital, Blaricum, the Netherlands. Normal breast
tissue (n = 13) was taken from reduction mammoplasties
performed on premenopausal patients without proliferative
breast disease. Specimens of pure ductal hyperplasia
(n = 11), pure DCIS (n = 21), and stage I/II invasive
ductal carcinoma (n = 40) were obtained from excision
biopsy procedures or mastectomies. The DCIS and invasive
cancer grades did not seem to influence correlations with
blood or lymph vessels, so different grade lesions were simply
grouped as DCIS or invasive cancer for further analysis.
None of the patients with invasive breast cancer had
received preoperative treatment. All specimens were fixed in
neutral 4% buffered formaldehyde. In our hospitals, anony-
mous use of left over patient material for scientific purposes
is a standard item in the treatment contract, although the
wishes of those patients who object to this are respected.
Immunohistochemistry
Immunohistochemistry was performed on 4 mm thick slides.
After dewaxing and rehydration, endogenous peroxidase
activity was blocked for 30 minutes in methanol containing
0.3% hydrogen peroxide. For CD31 staining, antigen retrieval
was performed by autoclave treatment for 20 minutes in
citrate buffer (pH 6.0). After antigen retrieval, a cooling off
period of 20 minutes preceded incubation with the primary
antibody. Tissue sections were incubated with saturating
concentrations of primary antibody (mouse monoclonal JC-
70; Dako, Glostrup, Denmark), diluted at 1/40 in phosphate
buffered saline with 5% bovine serum albumin. Thereafter,
the Labvision system (Dako) was used according to the
manufacturer’s instructions.
For LYVE-1 staining, antigen retrieval was performed by
microwave treatment (four minutes at 750 W, four minutes
at 360 W) in a 0.1M Tris/HCl, pH 9.0, 2mM EDTA solution.
After antigen retrieval, a cooling off period of 20 minutes
preceded preincubation for 15 minutes in Tris buffered saline
(TBS) containing 5% normal human serum (NHS), after
which the primary antibody (anti-LYVE-1; rabbit polyclonal;
kindly provided by DJ Jackson, Oxford, UK) was added at a
dilution of 1/100 in TBS with 5% NHS. Next, an enhanced
peroxidase staining method (Envision; Dako) was used
according to the manufacturer’s instructions. All sections
were developed with diaminobenzidine (Dako) and then
briefly counterstained with haematoxylin.
Quantification
Blood and lymph vessels were counted using an ocular grid at
a magnification of6400. To this end, in four adjacent fields
of vision in the most vascularised area (the hot spot; total
area, 0.6 mm2), microvessels were counted and expressed as
the blood vessel density (BVD) or LVD/mm2, as described
previously.23 24 These assessments were carried out by two
observers (MMV and PJvD).
Statistical analysis
The non-parametric Mann Whitney test for independent
samples (SPSS for Windows version 9.01, 1999; SPSS Inc,
Chicago, Illinois, USA) was used to compare LVD and BVD
between the different groups. Correlations between BVD and
LVD on the one hand and lesion size on the other were
compared with Fisher’s exact test. Two sided p values , 0.05
were considered to be significant.
RESULTS
Lymphatic vessel patterns in the normal breast
Stromal breast lymph vessels strongly expressed LYVE-1
(fig 1A). LYVE-1 positive lymph vessels were large irregular
vessels with empty lumina covered with one layer of non-
atypical endothelium. Occasionally, LYVE-1 positive tissue
macrophages were seen in the interlobular stroma. Blood
vessels were negative for LYVE-1, as can be seen from the
surrounding LYVE-1 negative vessels with intraluminal
erythrocytes (fig 1A, arrow). This observation confirms the
specificity of LYVE-1 for human breast lymph vessels.
LYVE-1 positive lymph vessels were dispersed in the
interlobular stroma, smooth muscle, and adipose tissue. In
these areas, lymph vessels were often arranged in linear
patterns, probably leading to local draining lymph nodes.
Most of the lymph vessels were seen in conjunction with
blood vessels. In some cases, lymph vessels were seen lying
around a blood vessel. Remarkably, no lymph vessels were
seen within the breast lobuli.
CD31 positive blood vessels were seen throughout the
tissue in normal breast. In the interlobular stroma, larger
vessels were present, often accompanied by numerous micro-
vessels. Around the lobuli and in the intralobular stroma,
mainly microvessels were seen (fig 1B).
Premalignant breast lesions show no increase of
intralesional lymph vessels
Similar results were obtained for usual hyperplasia as those
seen for normal breast, with no increase in LVD or BVD
(fig 1C; table 1). In DCIS lesions, breast lymph vessels were
present in only the interlobular stroma and the adipose tissue
surrounding the lesions (fig 1D). These vessels showed
similar morphology to the lymph vessels seen in normal
breast tissue.
In DCIS lesions, no LYVE-1 positive lymph vessels were
found lying directly around the ducts, in contrast to blood
vessels, which were often seen as a vascular rim around
the DCIS lesions (fig 1E), as noted previously.24 Indeed, the
LVD was not significantly different in DCIS compared with
normal breast (p = 0.06), but BVD was much higher
(p , 0.001; table 1). The size of the DCIS lesion correlated
inversely with LVD (p = 0.02). This association was not
found for BVD (table 2).
Intratumorous lymph vessels are absent from most
invasive breast carcinomas
Thirty one of 40 invasive breast cancer cases showed
complete absence of intratumorous lymphatics (fig 1F). In
nine of 40 cases, some intratumorous lymph vessels were
seen with comparable morphology to normal breast lympha-
tics (fig 1G). In most of these cases, peritumorous lymphatics
were present at the tumour margin, with infiltrating tumour
islands between these vessels. The surrounding ‘‘normal’’
tissue showed normal lymphatics also. Occasionally, these
peritumorous lymphatics appeared to be somewhat enlarged
and more complex than normal breast lymphatics. However,
other cases just showed small lymph vessels with decreased
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numbers of lymphatics compared with normal breast tissue.
Peritumorous lymphatics were often seen in association with
LYVE-1 positive tissue macrophages. In some cases, invasion
of the lymphatic vessels by tumour cells was seen intratu-
morously at the periphery, or peritumorously. Intratumorous
LVD was much lower than that seen in normal breast tissue
(p , 0.001), and showed no relation to tumour size.
Intratumorous BVD was significantly higher (p , 0.001)
than that seen in normal breast tissue (table 1; fig 1H).
Peritumorous LVD was not significantly different from
normal breast tissue (p = 0.07), and showed no correlation
with tumour size (p = 0.364; table 3).
DISCUSSION
The spread of tumour cells via the lymphatic system is one of
the major causes of tumour metastasis. However, a func-
tional intratumorous lymphatic system seems to be absent
from most cancer types.22 To date, there have been many
Figure 1 Lymph and blood vessel
patterns in the normal human breast,
premalignant lesions, and invasive
breast cancer. (A) In the normal breast,
scattered lymph vessels are seen in the
interlobular stroma. No intralobular
lymph vessels are seen. Arrow:
unstained blood vessel associated with
lymph vessels. (B) In the normal breast,
numerous blood vessels are seen, also
in the intralobular space. (C) Lymph
vessels are present at some distance in
the adipose tissue surrounding usual
ductal hyperplasia. (D) Ductal
carcinoma in situ with lymph vessels in
the surrounding stroma at some
distance from the neoplastic ducts.
(E) Blood vessels are present as a
vascular rim around a ductal carcinoma
in situ. (F) In invasive breast cancer,
lymphatics are seen at the tumour
margin, but are absent from the
intratumorous stroma in most cases.
(G) In invasive breast cancer,
intratumorous lymphatics are seen
occasionally in the intratumorous
stroma in some cases. (H) In invasive
breast cancer, intratumorous blood
vessels are dispersed within the tumour.
Table 1 BVD and LVD counted in the ‘‘hot spots’’ in normal breast and in (pre)malignant breast lesions
Tissue N BVD p Value* LVD p Value* Lesion size (cm) p Value*
Normal breast 13 41 (2.8) NA 21 (19) NA NA
Hyperplasia 11 54 (12.0) 0.417 16.8 (10.0) 0.691 NA
DCIS 21 140.9 (58.6) ,0.001 11.5 (11.0) 0.062 0.43 (0.26; 0.1–1.4)
Invasive cancer
(intratumorous)
40 110.1 (57.2) ,0.001 1.9 (4.6) ,0.001 2.8 (1.25; 1.0–6.0) 0.001
*Mann-Whitney test, in relation to normal breast.
Values are mean (SD; range (for lesion size)).
BVD, blood vessel density (in mm2); DCIS, ductal carcinoma in situ; LVD, lymph vessel density (in mm2); NA, not applicable.
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hypotheses to explain the absence of intratumorous lympha-
tics.25–33 To differentiate between the hypothesis of total
collapse of newly formed lymph vessels because of a rise in
interstitial pressure and the total absence of lymphangiogen-
esis, we investigated lymph vessel patterns in normal breast,
premalignant breast lesions, and invasive breast cancers.
‘‘The inverse correlation between lymph vessel density and
the lesion size in ductal carcinoma in situ could be
explained by the replacement of stroma by tumour
epithelium, rather than the collapse of lymph vessels’’
For the first time, lymphangiogenesis was studied in
premalignant breast lesions. In ductal hyperplasia, an early
proliferative breast lesion,34 35 neither LVD nor BVD was
increased in comparison with normal breast tissue. In DCIS,
the final non-invasive stage of breast cancer development,
BVD was increased, with extensive vascular rimming,
indicating that the angiogenic switch had taken place.
These results are in accordance with those from other groups
(the importance of angiogenesis in DCIS is reviewed in
Rice and Quinn36). However, LVD was not increased. Because
it is unlikely that interstitial pressure is increased in these
small premalignant lesions, the collapse of newly formed
lymph vessels can hardly explain the absence of lymph
vessels. Furthermore, even collapsed lymph vessels would
be expected to retain the expression of LYVE-1 in the
endothelium. Therefore, the inverse correlation between LVD
and the lesion size in DCIS could be explained by the
replacement of stroma by tumour epithelium, rather than the
collapse of lymph vessels. Thus, lymphangiogenesis simply
seems to be lacking during breast carcinogenesis. This idea is
supported by the complete absence of intratumorous lym-
phatics in most invasive breast cancers. We hypothesise that
this is the result of a completely destructive growth pattern,
where the pre-existing stroma is destroyed and replaced by
newly formed tumour stroma lacking lymph vessels. LVD was
present in a few invasive cancers, but it was much lower than
in normal breast tissue, pointing to an incompletely
destructive growth. In addition, at the peritumorous margin,
LVD was not higher than in normal tissue. These results are
in agreement with the observation of other groups for breast37
and other cancer types.21 22 All these results indicate that the
absence of intratumorous lymphatics can be explained by the
absence of lymphangiogenesis.
The absence of lymphangiogenesis during breast cancer
progression might be explained by the absence of lymphan-
giogenic growth factors, such as VEGF-C and VEGF-D, or the
absence of expression of their receptors. Because over-
expression of VEGF-C/D has been found in many tumour
types, including breast cancer,38 this is not a plausible
explanation. This also holds true for the expression of the
lymph vessel specific VEGF-C/VEGF-D receptor, VEGFR-3
(flt-4), which was also found to be expressed on blood vessels
in various cancer types, including breast cancer.5
Invasion related proteins are involved in matrix degrada-
tion to support processes such as angiogenesis,39 although
whether or not matrix degradation occurs in lymphangiogen-
esis is still unclear. However, the invasion related proteins
involved in this process are different from those thought to be
important for blood vessel formation.40 Therefore, changes in
matrix composition, as seen in cancer, may lead to
disturbances in the initiation of lymphangiogenesis, as a
result of the absence of appropriate invasion related proteins.
Other inhibitors of lymphangiogenic growth might be
factors released by the tumour cells themselves, or properties
of the dividing tumour cells that directly cause destruction of
lymph vessels. This has also been proposed by Williams et al.37
In their study, an inverse relation was found between tumour
aggressiveness and the absence of intratumorous lymphatics
in invasive breast cancer. Furthermore, low LVD was found to
be predictive of poor prognosis. Their results suggest that
lymph vessels are invaded and destroyed by naturally
occurring breast carcinomas. These findings are in agreement
with our observations, which have shown that intratumorous
lymphangiogenesis does not occur during breast carcinogen-
esis. However, because intratumorous lymphangiogenesis is
seen in some other tumour types, such as head and neck cell
carcinoma and melanoma,14–18 tissue specific tumour features
might also be responsible for the presence or absence of a
‘‘lymphangiogenic switch’’. Further studies on the molecular
basis of lymphangiogenic inhibitors during carcinogenesis
should consider this.
The absence of intratumorous lymphangiogenesis in most
cancer types has important consequences. First, because no
functional lymphatics are present, lymphatic metastasis
should occur via the pre-existing peritumorous lymphatics.
These will mostly only be present at or outside the tumour
margin. Indeed, it has long be suggested that lymph vessel
invasion as a diagnostic feature should only consider tumour
emboli outside the tumour margin to be reproducible.41 In
retrospect, this is a fortunate decision because intratumorous
lymphatic invasion is now known to be too rare to be
diagnosed reliably. Second, intratumorous blood vessels
are often leaky.42 In view of the absence of a functional
intratumorous lymphatic network, it is surprising that
Table 2 Correlation between lesion size and vessel
density of breast DCIS (n = 21)
LVD BVD
Low (,10) High (>10) Low (,75) High (>75)
DCIS size
0–4 mm 2 7 6 3
4–14 mm 9 3 9 3
p =0.017 p=0.676
BVD, blood vessel density (in mm2); DCIS, ductal carcinoma in situ; LVD,
lymph vessel density (in mm2).
Table 3 Correlation between lesion size and vessel density of invasive carcinomas
(n = 40)
LVD LVD-IT BVD-IT
Low (,25) High (>25) Absent Present Low (,75) High (>75)
Tumour size
0–2 cm 8 6 12 2 5 9
2–5 cm 16 6 17 5 9 13
.5 cm 4 0 2 2 0 4
p=0.235 p =0.320 p =0.287
BVD, blood vessel density (in mm2); DCIS, ductal carcinoma in situ; IT, intratumorous; LVD, lymph vessel density (in
mm2).
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tumours do not show extremely high interstitial pressures.
We know from the sentinel node procedure that peritumor-
ously injected colloid tracers are efficiently transported to the
lymph nodes.43 Apparently, interstitial fluid finds its way to
the lymphatics through tissue spaces driven by the interstitial
pressure gradient. This suggests that the breast acts as a sort
of sponge.
In conclusion, although angiogenesis parallels the progres-
sion of premalignant breast lesions, lymphangiogenesis
appears to be lacking during breast carcinogenesis, resulting
in the complete absence of lymph vessels in most invasive
breast cancers. This points either to a lack of lymphangio-
genic growth stimuli or to the presence of inhibitors of
lymphangiogenic growth. The identification of factors other
than interstitial pressure rise that contribute to lymphangio-
genic growth inhibition might increase our knowledge about
the mechanisms of decreased tumour lymphangiogenesis and
the role of this phenomenon in tumour progression.
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